ATE260980T1 - Die erzielung hoher titer des rekombinanten aav- vektors - Google Patents

Die erzielung hoher titer des rekombinanten aav- vektors

Info

Publication number
ATE260980T1
ATE260980T1 AT95902421T AT95902421T ATE260980T1 AT E260980 T1 ATE260980 T1 AT E260980T1 AT 95902421 T AT95902421 T AT 95902421T AT 95902421 T AT95902421 T AT 95902421T AT E260980 T1 ATE260980 T1 AT E260980T1
Authority
AT
Austria
Prior art keywords
aav
packaging
vectors
gene therapy
achieve high
Prior art date
Application number
AT95902421T
Other languages
English (en)
Inventor
Terence R Flotte
Barrie J Carter
William B Guggino
Rikki Solow
Original Assignee
Targeted Genetics Corp
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targeted Genetics Corp, Univ Johns Hopkins filed Critical Targeted Genetics Corp
Application granted granted Critical
Publication of ATE260980T1 publication Critical patent/ATE260980T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95902421T 1993-11-09 1994-11-03 Die erzielung hoher titer des rekombinanten aav- vektors ATE260980T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14933293A 1993-11-09 1993-11-09
PCT/US1994/012587 WO1995013365A1 (en) 1993-11-09 1994-11-03 Generation of high titers of recombinant aav vectors

Publications (1)

Publication Number Publication Date
ATE260980T1 true ATE260980T1 (de) 2004-03-15

Family

ID=22529805

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95902421T ATE260980T1 (de) 1993-11-09 1994-11-03 Die erzielung hoher titer des rekombinanten aav- vektors

Country Status (11)

Country Link
US (1) US5658776A (de)
EP (1) EP0733103B1 (de)
JP (2) JPH09509564A (de)
AT (1) ATE260980T1 (de)
AU (1) AU688428B2 (de)
CA (1) CA2176117C (de)
DE (1) DE69433592T2 (de)
DK (1) DK0733103T3 (de)
ES (1) ES2216005T3 (de)
PT (1) PT733103E (de)
WO (1) WO1995013365A1 (de)

Families Citing this family (309)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755454B1 (de) 1994-04-13 2008-02-13 The Rockefeller University Aav-vermittelte überbringung von dna in zellen des nervensystems
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
EP0785991A1 (de) * 1994-10-13 1997-07-30 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Bereitstellung von rep-negativen aav-mutanten und hierfür verwendbare zellen
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US6342390B1 (en) 1994-11-23 2002-01-29 The United States Of America As Represented By The Secretary Of Health And Human Services Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
EP0796339A1 (de) * 1994-12-06 1997-09-24 Targeted Genetics Corporation Verpackungszelllinien zur bereitstellung rekombinanter aav vektoren mit einem hohen titer
US5843742A (en) * 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US20020103147A1 (en) 1997-09-05 2002-08-01 Hammond H. Kirk Gene therapy for congestive heart failure
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
WO1996026742A1 (en) 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6027931A (en) 1995-08-03 2000-02-22 Avigen, Inc. High-efficiency AA V helper functions
US5622856A (en) * 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US6001650A (en) * 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
ES2210391T3 (es) * 1995-08-03 2004-07-01 Avigen, Inc. Sistema auxiliar de alta eficacia para la produccion de vectores aav.
US6086913A (en) * 1995-11-01 2000-07-11 University Of British Columbia Liposomal delivery of AAV vectors
ES2219700T3 (es) * 1995-12-01 2004-12-01 Crucell Holland B.V. Expresion regulada de proteinas en celulas de mamiferos transfectadas de manera estable.
JP2002514899A (ja) * 1996-03-04 2002-05-21 ターゲティッド ジェネティックス コーポレイション 組換えａａｖベクターを用いて血管中の細胞を形質導入するための方法
US6245735B1 (en) 1996-07-29 2001-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating pseudomonas infection
IL128780A0 (en) * 1996-09-06 2000-01-31 Univ Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
IL128736A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania Methods using cre-lox for production of recombinant adeno-associated viruses
WO1998020140A1 (en) 1996-11-06 1998-05-14 The Regents Of The University Of California Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof
US6541258B2 (en) 1996-12-18 2003-04-01 Targeted Genetics Corporation AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
EP0856585A1 (de) * 1997-01-29 1998-08-05 Introgene B.V. Ein induzierbares Replications- und Expressionssystem
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
EP1005561A4 (de) * 1997-03-21 2004-03-31 Enzo Therapeutics Inc A Fully Vektor, virale vektoren und verpackungszelllinien zur deren vermehrung
US8703480B1 (en) 1997-03-21 2014-04-22 Enzo Therapeutics, Inc. Biological function effecting viral vectors and chimeric cells useful as packaging cell lines and target cells
DE69840439D1 (de) * 1997-04-24 2009-02-26 Univ Washington Zielgerichtete genveraenderung mit parvoviralen vektoren
US6689605B1 (en) 1997-05-22 2004-02-10 Uab Research Foundation Controlling immune response to specific antigens
WO1998052615A1 (en) * 1997-05-22 1998-11-26 Uab Research Foundation Controlling immune response to specific antigens
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) * 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2830694C (en) 1997-09-05 2018-02-27 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
CA2303768C (en) * 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
AU756827B2 (en) * 1997-10-21 2003-01-23 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRs) for use with recombinant AAV vectors
WO1999020779A1 (en) * 1997-10-21 1999-04-29 Targeted Genetics Corporation Amplifiable adeno-associated virus (aav) packaging cassettes for the production of recombinant aav vectors
US6346415B1 (en) * 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US6642051B1 (en) * 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
US6294379B1 (en) * 1998-02-25 2001-09-25 The Regents Of The University Of California Efficient AAV vectors
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US20060183228A1 (en) * 1998-03-24 2006-08-17 Enzo Therapeutics, Inc. Viral vectors with surface or envelope components
ATE269412T1 (de) 1998-04-24 2004-07-15 Univ Florida Rekombinanter adeno-assoziierter viraler vektor, der alpha-1 antitrypsin kodiert, zur gentherapie
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
WO2000005415A1 (en) * 1998-07-22 2000-02-03 Immusol Incorporated Substantially complete ribozyme libraries
EP1930418B1 (de) 1998-09-04 2015-04-08 Genzyme Corporation Verfahren zur Erzeugung helferfreier Präparate mit hohem Titer aus freigesetzten rekombinanten AAV-Vektoren
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US7129043B1 (en) 1998-10-22 2006-10-31 Duke University Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
DK1129064T3 (da) 1998-11-12 2008-04-28 Invitrogen Corp Transfektionsreagenser
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
NZ568033A (en) 1998-11-27 2011-04-29 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
JP4693244B2 (ja) * 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6893865B1 (en) * 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
ES2312344T3 (es) * 1999-05-28 2009-03-01 Targeted Genetics Corporation Metodos y composiciones para disminuir el nivel de factor de necrosis tumoral (tnf) en trastornos asociados con tnf.
EP1939300A1 (de) 1999-05-28 2008-07-02 Targeted Genetics Corporation Verfahren und Zusammensetzung zur Senkung des Spiegels des Tumornekrosefaktors (TNF) bei TNF-assoziierten Leiden
EP1916258B1 (de) 1999-08-09 2014-04-23 Targeted Genetics Corporation Erweiterte Expression einer einstämmigen, heterologen Nukleotidsequenz von rekombinanten viralen Vektoren durch Modellierung der Sequenz mit stammübergreifenden Basispaaren
ES2478635T3 (es) 1999-08-09 2014-07-22 Targeted Genetics Corporation Incremento de la expresión de una secuencia de nucleótidos heteróloga monocatenaria de vectores virales recombinantes diseñando la secuencia de modo que forma pares de bases intracatenarios
US7115391B1 (en) * 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
EP1224312A1 (de) * 1999-10-12 2002-07-24 The University of North Carolina at Chapel Hill Vektoren abgeleitet vom adeno-assoziierten virus, die für faktor-viii kodieren und verfahren zu ihrer verwendung
US6965010B2 (en) * 2000-02-25 2005-11-15 Licentia, Ltd. Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
AU2001280809A1 (en) * 2000-07-28 2002-02-13 University Of Maryland, Baltimore Accessory cholera enterotoxin and analogs thereof as activators of calcium dependent chloride channel
ATE405586T1 (de) 2001-05-08 2008-09-15 Darwin Molecular Corp Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
US7119172B2 (en) 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
AU2002303832A1 (en) 2001-05-21 2002-12-03 Beth Israel Deaconess Medical Center, Inc. P.aeruginosa mucoid exopolysaccharide specific binding peptides
US6844192B2 (en) 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
CA2476410C (en) * 2002-03-01 2013-09-24 Celltech R & D, Inc. Methods to increase or decrease bone density
US7510872B2 (en) * 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
EP2269658B1 (de) 2003-05-01 2018-12-19 Genzyme Corporation Genetherapie für neuro-stoffwechsel krankheiten
US20070037284A1 (en) * 2003-06-04 2007-02-15 Enzo Therapeutics, Inc. Vectors for expressing exogenous gene or exogenous nucleic acid sequences
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
US20050120398A1 (en) * 2003-09-12 2005-06-02 Vertex Pharmaceuticals Incorporated Animal model for HCV infection
US7422741B2 (en) 2004-03-05 2008-09-09 Vegenics Limited VEGFR-3 fusion proteins
US7319015B2 (en) * 2004-03-16 2008-01-15 The Regents Of The University Of Michigan Methods and compositions for using alveolar macrophage phospholipase A2
US7582442B2 (en) * 2004-03-16 2009-09-01 The Regents Of The University Of Michigan Methods and compositions for using aleveolar macrophage phospholipase A2
WO2006014798A2 (en) * 2004-07-27 2006-02-09 Mount Sinai School Of Medicine Methods and compositions for using sax2
FI20050753A (fi) 2004-09-03 2006-03-04 Licentia Oy Uudet peptidit
US7531523B2 (en) 2005-02-17 2009-05-12 Vertex Pharmaceuticals Incorporated Sodium channel protein type III alpha-subunit splice variant
CA2607173C (en) 2005-05-02 2018-04-24 Genzyme Corporation Composition comprising an adeno-associated virus vector having a serotype 1 capsid for use in treating lysosomal storage diseases or alzheimer's disease
PT1879623E (pt) * 2005-05-02 2012-12-20 Genzyme Corp Terapia génica para distúrbios da medula espinal
ATE502956T1 (de) 2005-08-15 2011-04-15 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
DK1969003T3 (da) 2005-12-14 2010-12-13 Hermo Pharma Ltd Anvendelser af et neurotrofisk faktor-protein
WO2007089780A2 (en) * 2006-01-30 2007-08-09 Licentia, Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
LT1986661T (lt) 2006-02-08 2018-12-10 Genzyme Corporation Nimano-piko a tipo ligos genų terapija
WO2007098281A2 (en) 2006-02-27 2007-08-30 Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
EP2548578B1 (de) 2006-05-17 2014-08-20 The Ludwig Institute for Cancer Research Targeting der Regulierung von Fettsäuretransportern durch VEGF-B zur Modulation menschlicher Krankheiten
HUE031156T2 (en) 2006-06-07 2017-06-28 Genzyme Corp Gene therapy for amyotrophic lateral sclerosis and other spinal cord diseases
US20100035973A1 (en) * 2006-07-17 2010-02-11 Nationwide Children's Hospital, Inc. Disruption of programmed death 1 (pd-1) ligand to adjuvant adeno-associated virus vector vaccines
CN101528922A (zh) 2006-10-03 2009-09-09 建新公司 肌萎缩性侧索硬化症和其它脊髓病症的基因治疗
CA2693178C (en) 2006-11-29 2018-12-04 Nationwide Children's Hospital, Inc. Myostatin inhibition for enhancing muscle and/or improving muscle function
US8454954B2 (en) 2007-05-16 2013-06-04 The Brigham And Women's Hospital, Inc. Treatment of synucleinopathies
SI2158322T1 (sl) 2007-06-06 2017-10-30 Genzyme Corporation Genska terapija za bolezni lizosomskega shranjevanja
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
EP2231164A1 (de) 2007-12-03 2010-09-29 The Regents of the University of California Oxysterole zur aktivierung von hedgehog-signalisierung, osteoinduktion, antiadipogenese und wnt-signalisierung
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
JP2011526916A (ja) 2008-06-30 2011-10-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 全身性紅斑性狼瘡を同定および処置するための診断標的および治療標的としてのリソソームホスホリパーゼａ２（ｌｐｌａ２）活性
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
CN102459611B (zh) 2009-05-02 2016-11-09 建新公司 神经退行性疾病的基因治疗
EP2767298A3 (de) 2010-11-23 2014-10-01 Presage Biosciences, Inc. Therapeutische Verfahren und Zusammensetzungen zur Abgabe in fester Form
WO2012145509A2 (en) 2011-04-19 2012-10-26 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors, and viruses
US10196636B2 (en) 2011-04-21 2019-02-05 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of myotilin
EP3495472B1 (de) 2011-04-21 2023-11-15 Nationwide Children's Hospital, Inc. Rekombinante virusprodukte und verfahren zur expressionshemmung von myotilin
AU2012255143A1 (en) 2011-05-19 2014-02-20 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
US20130039888A1 (en) 2011-06-08 2013-02-14 Nationwide Children's Hospital Inc. Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
EP3290055B1 (de) 2011-07-25 2024-08-28 Nationwide Children's Hospital, Inc. Rekombinante virusprodukte und verfahren zur expressionshemmung von dux4
CA2853379C (en) 2011-10-27 2020-11-24 Wellstat Ophthalmics Corporation Vectors encoding rod-derived cone viability factor
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
US9365496B2 (en) 2011-11-30 2016-06-14 Ludwig Institute For Cancer Research iNKT cell modulators and methods of using the same
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
CN104136601A (zh) 2012-02-17 2014-11-05 斯格本斯眼科研究所 人视网膜祖细胞的表型谱
CN104395331B (zh) 2012-05-07 2016-11-02 加利福尼亚大学董事会 诱导骨生成和hedgehog 信号传导且抑制脂肪形成的氧固醇类似物氧固醇化合物133
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
DK2879719T3 (en) 2012-08-01 2018-09-03 Nationwide Childrens Hospital INTRATEKAL ADMINISTRATION OF RECOMBINANT ADENOASSOCATED VIRUSES
EP2892617B1 (de) 2012-09-06 2018-06-13 The University of Chicago Antisense-polynukleotide zur induktion von exon-skipping sowie verfahren zur behandlung von muskeldystrophien
JP2015529685A (ja) 2012-09-17 2015-10-08 ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルＴｈｅ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ａｔｎａｔｉｏｎｗｉｄｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ 筋萎縮性側索硬化症の処置のための組成物および方法
PT2956476T (pt) 2013-02-18 2020-02-21 Vegenics Pty Ltd Moléculas de ligação e usos destas
WO2014168953A1 (en) 2013-04-08 2014-10-16 University Of Iowa Research Foundation Chimeric adeno-associated virus/ bocavirus parvovirus vector
EA032706B1 (ru) 2013-04-20 2019-07-31 Рисёрч Инститъют Эт Нэйшнвайд Чилдрен'С Хоспитал ДОСТАВКА НАЦЕЛЕННЫХ НА ЭКЗОН 2 ПОЛИНУКЛЕОТИДНЫХ КОНСТРУКЦИЙ U7snRNA ПРИ ПОМОЩИ РЕКОМБИНАНТНОГО АДЕНОАССОЦИИРОВАННОГО ВИРУСА
WO2014179756A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
EP3622821A1 (de) 2013-05-15 2020-03-18 Regents of the University of Minnesota Adenoassoziierter virenvermittelter gentransfer in das zentrale nervensystem
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
HUE061629T2 (hu) 2013-08-27 2023-07-28 Res Inst Nationwide Childrens Hospital Termékek és módszerek amyotrophiás lateralis sclerosis kezelésére
EP3039129B1 (de) 2013-08-30 2018-06-27 Amgen Inc. Herstellung rekombinanter aav-vektoren mit hohem titer in haftenden und hängenden zellen
CA2929669A1 (en) 2013-11-05 2015-05-14 The Research Institute At Nationwide Children's Hospital Compositions and methods for inhibiting nf-.kappa.b and sod-1 to treat amyotrophic lateral sclerosis
WO2015142984A1 (en) 2014-03-18 2015-09-24 Washington University Methods and compositions for red-shifted chromophore substitution for optogenetic applications
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
AU2015301978C1 (en) 2014-08-09 2022-06-09 Research Institute At Nationwide Children's Hospital Methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene
US10842886B2 (en) 2014-10-10 2020-11-24 Research Institute At Nationwide Children's Hospital Guided injections for AAV gene transfer to muscle
EP3215602B1 (de) 2014-11-05 2019-12-25 The Research Institute at Nationwide Children's Hospital Verfahren und materialien zur herstellung rekombinanter viren in eukaryotischen mikroalgen
EP3250279B1 (de) 2015-01-30 2020-08-19 The Regents of the University of California Spinales subpiales genfreisetzungssystem
MA41451A (fr) 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
CA2977455A1 (en) 2015-02-23 2019-09-01 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
WO2016164602A1 (en) 2015-04-08 2016-10-13 The University Of Chicago Compositions and methods for correcting limb girdle muscular dystrophy type 2c using exon skipping
US20180104289A1 (en) 2015-04-08 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Viral gene therapy as treatment for cholesterol storage disease or disorder
US10967073B2 (en) 2015-05-07 2021-04-06 The Mclean Hospital Corporation Glucocerebrosidase gene therapy for Parkinson's disease
RS63927B1 (sr) 2015-05-15 2023-02-28 Regenxbio Inc Povezani adenovirus za terapijsku isporuku u centralni nervni sistem
US10017832B2 (en) 2015-08-25 2018-07-10 Washington University Compositions and methods for site specific recombination at asymmetric sites
CN108136049A (zh) 2015-09-17 2018-06-08 全国儿童医院研究所 Galgt2基因治疗的方法和材料
AU2016339053A1 (en) 2015-09-24 2018-04-12 Crispr Therapeutics Ag Novel family of RNA-programmable endonucleases and their uses in genome editing and other applications
CA3000931A1 (en) 2015-10-28 2017-05-04 Crispr Therapeutics Ag Materials and methods for treatment of duchenne muscular dystrophy
CN109328231A (zh) 2015-11-06 2019-02-12 克里斯普治疗股份公司 用于治疗1a型糖原贮积病的材料和方法
EP3377042A4 (de) 2015-11-16 2019-05-29 The Research Institute at Nationwide Children's Hospital Materialien und verfahren zur behandlung von titinbasierten myopathien und anderen titinopathien
JP6932698B2 (ja) 2015-12-01 2021-09-08 クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ アルファ１アンチトリプシン欠乏症の治療のための材料および方法
SG11201805320XA (en) 2015-12-23 2018-07-30 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
US11938193B2 (en) 2016-01-08 2024-03-26 Washington University Compositions comprising chemerin and methods of use thereof
US20190038771A1 (en) 2016-02-02 2019-02-07 Crispr Therapeutics Ag Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
EP3416689B1 (de) 2016-02-18 2023-01-18 CRISPR Therapeutics AG Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn syndrome
US11066456B2 (en) 2016-02-25 2021-07-20 Washington University Compositions comprising TREM2 and methods of use thereof
WO2017147467A1 (en) 2016-02-26 2017-08-31 Research Institute At Nationwide Children's Hospital Recombinant virus products and methods for inducing dux4 exon skipping
MA43735A (fr) 2016-03-07 2018-11-28 Univ Iowa Res Found Expression médiée par aav utilisant un promoteur et un activateur synthétiques
WO2017158422A1 (en) 2016-03-16 2017-09-21 Crispr Therapeutics Ag Materials and methods for treatment of hereditary haemochromatosis
WO2017172606A1 (en) 2016-03-28 2017-10-05 The Regents Of The University Of California Method and composition for treating neuronal hyper-excitability
US11345913B2 (en) 2016-04-02 2022-05-31 Research Institute At Nationwide Children's Hospital Modified U6 promoter system for tissue specific expression
MA45477A (fr) 2016-04-15 2019-02-20 Res Inst Nationwide Childrens Hospital Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
MX2018012605A (es) 2016-04-15 2019-07-04 Res Inst Nationwide Childrens Hospital Administracion de vectores del virus adenoasociado de b-sarcoglicano y microarn-29 y el tratamiento de la distrofia muscular.
BR112018071321A2 (pt) 2016-04-18 2019-02-26 Crispr Therapeutics Ag materiais e métodos para tratamento de hemoglobinopatias
WO2017191503A1 (en) 2016-05-05 2017-11-09 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
EP3478828B1 (de) 2016-06-29 2024-09-04 CRISPR Therapeutics AG Materialien und verfahren zur behandlung von friedreich-ataxie und anderen verwandten erkrankungen
EP3478313B1 (de) 2016-06-29 2022-05-04 CRISPR Therapeutics AG Materialien und verfahren zur behandlung von amyotropher lateralsklerose (als) und anderen verwandten erkrankungen
CA3029132A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
CN118542952A (zh) 2016-07-06 2024-08-27 沃泰克斯药物股份有限公司 用于治疗疼痛相关病症的材料和方法
WO2018007871A1 (en) 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
WO2018020323A2 (en) 2016-07-25 2018-02-01 Crispr Therapeutics Ag Materials and methods for treatment of fatty acid disorders
US20190269799A1 (en) 2016-11-15 2019-09-05 Kanut LAOHARAWEE Method for improving neurological function in mpsi and mpsii and other neurological disorders
MX2019005874A (es) 2016-11-17 2020-02-07 Nationwide Childrens Hospital Inc Administracion intratecal de virus recombinante adeno-asociado que codifica la proteina 2 que une metilo-cpg.
US11753460B2 (en) 2016-12-13 2023-09-12 Seattle Children's Hospital Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
US11781116B2 (en) 2017-02-17 2023-10-10 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
US11407997B2 (en) 2017-02-22 2022-08-09 Crispr Therapeutics Ag Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
EP3585807A1 (de) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materialien und verfahren zur behandlung der parkinson-krankheit im frühstadium (park1) und anderer zustände oder störungen im zusammenhang mit dem synuclein-alpha (snca)-gen
WO2018154439A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
EP3585900B1 (de) 2017-02-22 2022-12-21 CRISPR Therapeutics AG Materialien und methoden zur behandlung von spinocerebellar ataxia typ 2 (sca2) und anderen spinocerebellar ataxia typ 2 protein (atxn2) gen verwandten erkrankungen oder störungen
WO2018154387A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Compositions and methods for gene editing
MA52112B1 (fr) 2017-03-17 2023-08-31 Res Inst Nationwide Childrens Hospital Administration par vecteur à virus adéno-associé de micro-dystrophine spécifique du muscle pour traiter la dystrophie musculaire
MA47800A (fr) 2017-03-17 2020-01-22 Univ Newcastle Délivrance par vecteur viral adéno-associé d'un fragment de micro-dystrophine pour traiter la dystrophie musculaire
JP7356354B2 (ja) 2017-05-12 2023-10-04 クリスパー セラピューティクス アクチェンゲゼルシャフト 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
EP3642345A1 (de) 2017-06-20 2020-04-29 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Codon-optimierte humane npc1-gene zur behandlung von morbus niemann-pick typ c1 und verwandten erkrankungen
EP3652324A1 (de) 2017-07-08 2020-05-20 Genethon Behandlung von spinaler muskelatrophie
CN110892064A (zh) 2017-07-25 2020-03-17 牛津遗传学有限公司 腺病毒载体
EP3697907A1 (de) 2017-10-17 2020-08-26 CRISPR Therapeutics AG Zusammensetzungen und verfahren zur geneditierung von hämophilie a
WO2019078916A1 (en) 2017-10-18 2019-04-25 Research Institute At Nationwide Children's Hospital ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION OF MUSCLE-SPECIFIC MICRO-DYSTROPHINE TO TREAT MUSCLE DYSTROPHY
CA3079416A1 (en) 2017-10-20 2019-04-25 Research Institute At Nationwide Children's Hospital Methods and materials for nt-3 gene therapy
US20210180091A1 (en) 2017-10-26 2021-06-17 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
IL274430B1 (en) 2017-11-08 2024-09-01 Novartis Gene Therapies Inc Means and method for preparing viral vectors and their uses
WO2019092505A1 (en) 2017-11-09 2019-05-16 Casebia Therapeutics Llp Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof
MA50877A (fr) 2017-11-21 2020-09-30 Bayer Healthcare Llc Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
MX2020005470A (es) 2017-11-27 2020-11-09 Coda Biotherapeutics Inc Composiciones y metodos para enfermedades neurologicas.
MA51138A (fr) 2017-12-14 2020-10-21 Bayer Healthcare Llc Nouveaux systèmes d'endonucléases arn-programmables et leurs utilisations dans l'édition de génome et d'autres applications
EP3728595A1 (de) 2017-12-21 2020-10-28 CRISPR Therapeutics AG Materialien und verfahren zur behandlung des usher-syndroms des typs 2a und/oder von nichtsyndromaler autosomaler rezessiver retinitis pigmentosa (arrp)
AU2018393050A1 (en) 2017-12-21 2020-06-18 Bayer Healthcare Llc Materials and methods for treatment of Usher Syndrome Type 2A
US20210254057A1 (en) 2018-01-12 2021-08-19 Crispr Therapeutics Ag Compositions and methods for gene editing by targeting transferrin
MA51787A (fr) 2018-02-05 2020-12-16 Vertex Pharma Substances et méthodes de traitement d'hémoglobinopathies
US11268077B2 (en) 2018-02-05 2022-03-08 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
EP3752616A1 (de) 2018-02-16 2020-12-23 CRISPR Therapeutics AG Zusammensetzungen und verfahren zur geneditierung durch targeting von fibrinogen-alpha
EP3768834A1 (de) 2018-03-19 2021-01-27 CRISPR Therapeutics AG Neuartige rna-programmierbare endonukleasesysteme und verwendungen davon
JP2021519581A (ja) 2018-04-03 2021-08-12 ストライドバイオ，インコーポレイテッド 抗体を回避するウイルスベクター
EP3774854A1 (de) 2018-04-03 2021-02-17 Stridebio, Inc. Antikörperausweichende virusvektoren
WO2019204668A1 (en) 2018-04-18 2019-10-24 Casebia Therapeutics Limited Liability Partnership Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
CA3091490A1 (en) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Rapamycin resistant cells
US20210255185A1 (en) 2018-06-08 2021-08-19 Novartis Ag Cell-based assay for measuring drug product potency
GB201809588D0 (en) 2018-06-12 2018-07-25 Univ Bristol Materials and methods for modulating intraocular and intracranial pressure
CA3104471A1 (en) 2018-06-18 2019-12-26 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies
BR112020025995A2 (pt) 2018-06-18 2021-03-23 Research Institute At Nationwide Children's Hospital administração de microdistrofina músculo-específica por vetor de vírus adeno-associado para tratar a distrofia muscular
SG11202012715UA (en) 2018-06-29 2021-01-28 Res Inst Nationwide Childrens Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
US20210324417A1 (en) 2018-08-29 2021-10-21 Research Institute At Nationwide Children's Hospital Products and methods for inhibition of expression of mutant gars protein
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
EP3867377A1 (de) 2018-10-17 2021-08-25 CRISPR Therapeutics AG Zusammensetzungen und verfahren zur abgabe von transgenen
CA3116630A1 (en) 2018-11-30 2020-06-04 Novartis Ag Aav viral vectors and uses thereof
EP3898995A1 (de) 2018-12-21 2021-10-27 Genethon Expressionskassetten für gentherapievektoren
US20220106592A1 (en) 2018-12-31 2022-04-07 Research Institute At Nationwide Children's Hospital DUX4 RNA Silencing Using RNA Targeting CRISPR-CAS13b
SG11202107986YA (en) 2019-02-04 2021-08-30 Res Inst Nationwide Childrens Hospital Adeno-associated virus delivery of cln3 polynucleotide
MX2021009404A (es) 2019-02-04 2021-11-12 Res Inst Nationwide Childrens Hospital Administracion del virus adenoasociado de polinucleotido de cln6.
AU2020221340A1 (en) 2019-02-15 2021-09-16 Bayer Healthcare Llc Gene editing for hemophilia A with improved Factor VIII expression
BR112021016570A2 (pt) 2019-02-26 2021-11-03 Res Inst Nationwide Childrens Hospital Entrega de vetor de vírus adenoassociado de beta-sarcoglicano e tratamento de distrofia muscular
US20220145274A1 (en) 2019-03-12 2022-05-12 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
KR20220044899A (ko) 2019-04-15 2022-04-12 유니버시티 오브 아이오와 리써치 파운데이션 낭성 섬유증의 치료를 위한 조성물 및 방법
AU2020257208A1 (en) 2019-04-15 2021-11-11 Research Institute At Nationwide Children's Hospital Gene therapy for treating or preventing visual effects in Batten disease
US20220195461A1 (en) 2019-04-15 2022-06-23 University Of Iowa Research Foundation Methods and compositions for transgene expression
EP3966327A1 (de) 2019-05-08 2022-03-16 Vertex Pharmaceuticals Incorporated Crispr/cas all-in-two-vektorsystemen zur behandlung von dmd
AU2020278499A1 (en) 2019-05-17 2022-01-06 Research Institute At Nationwide Children's Hospital Improved delivery of gene therapy vectors to retinal cells using a glycoside hydrolase enzyme
EP3990636A1 (de) 2019-06-28 2022-05-04 CRISPR Therapeutics AG Materialien und verfahren zur steuerung der geneditierung
CN114174514A (zh) 2019-07-25 2022-03-11 诺华股份有限公司 可调节的表达系统
SI4017871T1 (sl) 2019-08-21 2024-06-28 Research Institute At Nationwide Children's Hospital Dostava alfa-sarkoglikana z adeno povezanim virusnim vektorjem in zdravljenje mišične distrofije
AU2020334147A1 (en) 2019-08-21 2022-03-31 Trames Bio, Inc. Compositions and methods for neurological diseases
US20230416776A1 (en) 2019-10-08 2023-12-28 Regents Of The University Of Minnesota Crispr-mediated human genome editing with vectors
EP4045525A1 (de) 2019-10-17 2022-08-24 Stridebio, Inc. Adeno-assoziierte virusvektoren zur behandlung der niemann-pick-krankheit vom typ c
EP4045662A1 (de) 2019-10-18 2022-08-24 Research Institute at Nationwide Children's Hospital Materialien und verfahren zur behandlung von krankheiten, die mit mutationen im irf2bpl-gen einhergehen
JP2022552015A (ja) 2019-10-18 2022-12-14 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 蝸牛細胞を標的とする遺伝子治療
AU2020385387A1 (en) 2019-11-22 2022-06-02 Fondazione Irccs Ca' Granda Ospedale Maggiore Foliclinico Materials and methods for treatment of disorders associated with the IGHMBP2 gene
US20230227515A1 (en) 2019-12-20 2023-07-20 Research Institute At Nationwide Children's Hospital Optimized gene therapy for targeting muscle in muscle diseases
JP2023513932A (ja) 2020-02-18 2023-04-04 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｘ連鎖障害の治療におけるｍｉＲＮＡのＡＡＶ媒介標的化
CN115379863A (zh) 2020-04-14 2022-11-22 吉尼松公司 用于治疗酸性神经酰胺酶缺乏症的载体
JP2023530974A (ja) 2020-06-15 2023-07-20 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 筋ジストロフィーのためのアデノ随伴ウイルスベクター送達
WO2022006253A2 (en) 2020-06-30 2022-01-06 University Of Iowa Research Foundation Methods and compositions for administering recombinant viral vectors
WO2022011099A1 (en) 2020-07-08 2022-01-13 Regents Of The University Of Minnesota Modified hexosaminidase and uses thereof
WO2022018638A1 (en) 2020-07-21 2022-01-27 Crispr Therapeutics Ag Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
US20230414787A1 (en) 2020-08-27 2023-12-28 University Of Iowa Research Foundation Gene knock-out for treatment of glaucoma
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
TW202227634A (zh) 2020-09-08 2022-07-16 美商薩羅塔治療公司 表現γ—肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療
AU2021345112A1 (en) 2020-09-15 2023-04-27 Research Institute At Nationwide Children's Hospital Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy
US20240261434A1 (en) 2020-09-28 2024-08-08 Research Institute At Nationwide Children's Hospital Products and methods for treating muscular dystrophy
US20220290136A1 (en) 2020-09-30 2022-09-15 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis
WO2022076556A2 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
EP4251752A1 (de) 2020-11-30 2023-10-04 Research Institute at Nationwide Children's Hospital Zusammensetzungen und verfahren zur behandlung von fazioskapulohumeraler muskeldystrophie (fshd)
US20220228142A1 (en) 2020-12-17 2022-07-21 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
EP4284413A1 (de) 2021-01-27 2023-12-06 Research Institute at Nationwide Children's Hospital Materialien und verfahren zur behandlung von lysosomaler saurer lipase (lal-d)
KR20230138949A (ko) 2021-02-03 2023-10-05 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 Dux4 과발현과 연관된 질환을 치료하기 위한 조성물 및 방법
EP4288556A1 (de) 2021-02-05 2023-12-13 Regents of the University of Minnesota Verfahren zur prävention von herz- oder skelettdefekten bei krankheiten einschliesslich mucopolysaccharidosen
WO2022170038A1 (en) 2021-02-05 2022-08-11 Amicus Therapeutics, Inc. Adeno-associated virus delivery of cln3 polynucleotide
EP4301462A1 (de) 2021-03-04 2024-01-10 Research Institute at Nationwide Children's Hospital Produkte und verfahren zur behandlung von dystrophinbasierten myopathien mit crispr-cas9 zur korrektur von dmd-exon-duplikationen
EP4305157A1 (de) 2021-03-09 2024-01-17 Huidagene Therapeutics (Singapore) Pte. Ltd. Manipuliertes crispr/cas13-system und verwendungen davon
US20240189452A1 (en) 2021-04-13 2024-06-13 Research Institute At Nationwide Children's Hospital Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2 for Treating PITT Hopkins Syndrome VIA Intrathecal Delivery
AU2022256510A1 (en) 2021-04-15 2023-11-30 Spirovant Sciences, Inc. Methods and compositions for treatment of cystic fibrosis
JP2024515720A (ja) 2021-04-23 2024-04-10 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 筋ジストロフィーを治療するための製品及び方法
EP4334447A1 (de) 2021-05-07 2024-03-13 UCL Business Ltd Abca4-genomeditierung
WO2022245675A1 (en) 2021-05-17 2022-11-24 Sarepta Therapeutics, Inc. Production of recombinant aav vectors for treating muscular dystrophy
EP4108263A3 (de) 2021-06-02 2023-03-22 Research Institute at Nationwide Children's Hospital Rekombinante adeno-assoziierte virusprodukte und verfahren zur behandlung von gliedergürtel-muskeldystrophie 2a
EP4101928A1 (de) 2021-06-11 2022-12-14 Bayer AG Programmierbare typ-v-rna-endonukleasesysteme
EP4352214A1 (de) 2021-06-11 2024-04-17 Bayer AG Typ-v-rna-programmierbare endonukleasesysteme
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
EP4384628A2 (de) 2021-08-11 2024-06-19 Solid Biosciences Inc. Behandlung von muskeldystrophie
EP4144841A1 (de) 2021-09-07 2023-03-08 Bayer AG Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
EP4402265A1 (de) 2021-09-16 2024-07-24 Novartis AG Neue transkriptionsfaktoren
WO2023060215A1 (en) 2021-10-07 2023-04-13 Research Institute At Nationwide Children's Hospital Products and methods for myelin protein zero silencing and treating cmt1b disease
EP4413376A1 (de) 2021-10-08 2024-08-14 Amicus Therapeutics, Inc. Biomarker für lysosomale speicherkrankheiten
JP2023059858A (ja) 2021-10-15 2023-04-27 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用
EP4186919A1 (de) 2021-11-30 2023-05-31 Research Institute at Nationwide Children's Hospital Selbstkomplementärer adeno-assoziierter virusvektor und dessen verwendung bei der behandlung von muskeldystrophie
EP4198047A1 (de) 2021-12-16 2023-06-21 Genethon Erhöhung des gentransfers von fukutin-verwandtem protein unter verwendung modifizierter itr-sequenzen
EP4198046A1 (de) 2021-12-16 2023-06-21 Genethon Erhöhung des gentransfers von alpha-sarcoglykan unter verwendung von modifizierten itr-sequenzen
EP4198048A1 (de) 2021-12-16 2023-06-21 Genethon Calpain-3-gentransfersteigerung unter verwendung von modifizierten itr-sequenzen
EP4198134A1 (de) 2021-12-16 2023-06-21 Genethon Transfererhöhung des gamma-sarcoglycan-gens unter verwendung von modifizierten itr-sequenzen
AU2022420596A1 (en) 2021-12-21 2024-07-11 Research Institute At Nationwide Children's Hospital Materials and methods for the treatment of limb girdle muscular dystrophy
WO2023118068A1 (en) 2021-12-23 2023-06-29 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023166425A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
AU2023227586A1 (en) 2022-03-03 2024-09-12 Research Institute At Nationwide Children's Hospital Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
WO2023214346A1 (en) 2022-05-06 2023-11-09 Novartis Ag Novel recombinant aav vp2 fusion polypeptides
WO2023240177A1 (en) 2022-06-08 2023-12-14 Research Instiitute At Nationwide Children's Hospital Products and methods for treating diseases or conditions associated with mutant or pathogenic kcnq3 expression
WO2023237587A1 (en) 2022-06-10 2023-12-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2024011115A1 (en) 2022-07-06 2024-01-11 Research Institute At Nationwide Children's Hospital Adeno-associated virus delivery of cln1 polynucleotide
WO2024035782A1 (en) 2022-08-10 2024-02-15 Aav Gene Therapeutics, Inc. Aav-mediated intramuscular delivery of insulin
WO2024064913A1 (en) 2022-09-23 2024-03-28 Sarepta Therapeutics, Inc. Recombinant aav vectors for treating muscular dystrophy
WO2024081706A1 (en) 2022-10-11 2024-04-18 Research Institute At Nationwide Children's Hospital Adeno-associated virus delivery to treat spinal muscular atrophy with respiratory distress type 1 (smard1) and charcot-marie-tooth type 2s (cmt2s)
WO2024086747A1 (en) 2022-10-19 2024-04-25 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity
WO2024092171A1 (en) 2022-10-26 2024-05-02 University Of Iowa Research Foundation Method to deliver large genes using virus and a dna recombination system
WO2024092126A1 (en) 2022-10-27 2024-05-02 Cargo Therapeutics, Inc. Compositions and methods for improved immunotherapies
WO2024129743A2 (en) 2022-12-13 2024-06-20 Bluerock Therapeutics Lp Engineered type v rna programmable endonucleases and their uses
WO2024151982A1 (en) 2023-01-13 2024-07-18 Amicus Therapeutics, Inc. Gene therapy constructs for the treatment of pompe disease
WO2024163560A1 (en) 2023-02-01 2024-08-08 Sarepta Therapeutics, Inc. Raav production methods
WO2024168276A2 (en) 2023-02-09 2024-08-15 Cargo Therapeutics, Inc. Compositions and methods for immunotherapies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU7906691A (en) * 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
AU1150792A (en) * 1990-12-06 1992-07-08 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Inhibition of human immunodeficiency virus by an adeno-associated virus gene for human cells
ES2220923T3 (es) * 1993-11-09 2004-12-16 Medical College Of Ohio Lineas celulares estables capaces de expresar el gen de replicacion del virus adeno-asociado.

Also Published As

Publication number Publication date
ES2216005T3 (es) 2004-10-16
EP0733103B1 (de) 2004-03-03
JPH09509564A (ja) 1997-09-30
US5658776A (en) 1997-08-19
DK0733103T3 (da) 2004-07-12
JP2005110694A (ja) 2005-04-28
AU1129395A (en) 1995-05-29
PT733103E (pt) 2004-07-30
EP0733103A4 (de) 1997-12-17
WO1995013365A1 (en) 1995-05-18
CA2176117A1 (en) 1995-05-18
AU688428B2 (en) 1998-03-12
CA2176117C (en) 2006-01-03
DE69433592T2 (de) 2005-02-10
EP0733103A1 (de) 1996-09-25
DE69433592D1 (de) 2004-04-08

Similar Documents

Publication Publication Date Title
ATE260980T1 (de) Die erzielung hoher titer des rekombinanten aav- vektors
CA2435972A1 (en) Matrix attachment regions and methods for use thereof
ATE221916T1 (de) Synthetische dna-sequenz mit verstärkter isektizider aktivität in mais
AU4427389A (en) Peptides and antibodies that inhibit integrin-ligand binding
ATE270342T1 (de) Endosomolytisch wirksame partikel
EP0710288A4 (de) Adenovirale vektoren für die behandlung der hämophilie
DE3484664D1 (de) Rekombinante immunoglobulin-praeparate, verfahren zu ihrer herstellung, dna-sequenzen, expressionsvektoren und rekombinante wirkzellen hierfuer.
AR018101A1 (es) UNA REGION VARIABLE DE UNA CADENA LIGERA Y DE UNA CADENA PESADA, MOLECULAS DE ACIDO NUCLEICO QUE LAS CODIFICAN, VECTORES DE EXPRESIoN, ANTICUERPOS QUIMERICOS QUE SE ENLAZAN A CD40 HUMANO, ANTICUERPOS HUMANIZADOS Y COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHAS CADENAS.
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
DE69933550D1 (de) Modifizierte adenoviren welche ein faserersatzprotein enthalten
ATE256196T1 (de) Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
AU2220800A (en) Compositions and methods for packaging of alphavirus vectors
IL122206A0 (en) Adeno-associated virus vectors for gene expression
DE69930625D1 (de) Rekombinante aav-vektoren für die gentherapie von hämophilie a
DK0817858T3 (da) Vektorer, som indeholder terapeutiske gener for antimikrobielle peptider, til anvendelse ved genterapi
DE59109072D1 (de) Klonierung der N-Methylhydantoinase
ES2127192T3 (es) Polipeptidos especificos del epididimo y su aplicacion.
HK1011924A1 (en) Monoclonal antibodies to antigens expressed by hematopoietic facilitaroy cells.
Fischer Gene therapy: some results, many problems to solve.
AU5104096A (en) Novel recombinant dna vectors for gene therapy
BR9506666A (pt) Construçao de DNA vetor de express o replicável processo para a preparaçao de uma bactéria atenuada célula hospedeira composiçao de vacina e processo para o tratamento ou profilaxia de uma infecçao em um mamifero por exemplo um humano
AU1275095A (en) Antiviral composition of viral protein trans-dominant variants
ES2175184T3 (es) Virus que expresan proteinas toxicas y leneas celulares productoras.
TH22679B (th) การเอ็กซ์เพรสโพลีเพพไทด์ของไวรัสก่อโรคทางระบบหายใจที่แพร่พันธุ์ได้ในสุกรในเซลล์เดียวกัน
RU94006028A (ru) Днк, вектор, белок, клетки, растения и семена

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0733103

Country of ref document: EP

REN Ceased due to non-payment of the annual fee